Talazoparib for the Treatment of Metastatic Castration-resistant Prostate Cancer
Authors:
- 25 November 2024
- journal article
- review article
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
- Vol. 48 (4) , 206-214
Abstract
Breast and prostate cancer are among the most commonly diagnosed cancers worldwide. Recent advances in tumor sequencing and gene studies have led to a paradigm shift from treatment centered on the type of tumor to therapy more focused on specific immune phenotype markers and molecular alterations. In this review, we discuss the utility and function of talazoparib concerning prostate cancer treatment and summarize recent and planned clinical trials on talazoparib. We searched medical databases for articles relating to the use of talazoparib in prostate cancer from inception. Poly ADP ribose polymerase (PARP) is a family of 17 necessary DNA repair enzymes responsible for base excision repair, single-strand break repair, and double-strand break repair. PARP inhibitors are a class of oral targeted therapies that compete for the NAD+ binding site on PARP molecules. Talazoparib, a potent PARP inhibitor, has emerged as a significant therapeutic option in the treatment of metastatic castration-resistant prostate cancer (mCRPC), particularly for patients with specific genetic alterations. Its role as a PARP inhibitor makes it a targeted therapy, focusing on cancer cells with DNA repair deficiencies. Talazoparib’s role as a biomarker-directed therapy in advanced prostate cancer has been increasingly recognized. The TALAPRO-1 demonstrated durable antitumor activity in mCRPC patients. TALAPRO-2 is a notable clinical trial, specifically examining the effectiveness of Talazoparib when used in combination therapies. Current investigations demonstrate a significant improvement in survival outcomes for the patients of mCRPC, making Talazoparib a promising intervention.Keywords
This publication has 76 references indexed in Scilit:
- Pharmacokinetics, safety, and antitumor activity of talazoparib monotherapy in Chinese patients with advanced solid tumorsInvestigational New Drugs, 2023
- Pamiparib in patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutations: a phase II studyBreast Cancer Research and Treatment, 2022
- Efficacy and safety of talazoparib in Japanese patients with germline BRCA-mutated locally advanced or metastatic breast cancer: results of the phase 1 dose-expansion studyBreast Cancer, 2022
- 581P Patient (pt) reported pain in men with metastatic castration-resistant prostate cancer (mCRPC) receiving talazoparib (TALA): TALAPRO-1Annals of Oncology, 2021
- Pamiparib: First ApprovalDrugs, 2021
- Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trialAnnals of Oncology, 2020
- Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and BeyondDrugs in R&D, 2020
- Breast Cancer TreatmentJAMA, 2019
- Screening and Detection of Prostate Cancer—Review of Literature and Current PerspectiveIndian Journal of Surgical Oncology, 2017
- Phase 1 dose-escalation study of the PARP inhibitor CEP-9722 as monotherapy or in combination with temozolomide in patients with solid tumorsCancer Chemotherapy and Pharmacology, 2014